Biosimilars Program Could 'Explode,' Woodcock Warns Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER director expresses concerns about lack of resources coupled with growing workload.
You may also be interested in...
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.
PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?
Success of enhanced communications in particular made one stakeholder wonder whether FDA could use it with non-breakthrough applications.